German China

UK: Biopharmaceutical Purification GE Healthcare to Open Biotechnology Manufacturing Center in 2019

Editor: Alexander Stark

GE Healthcare announced the opening of a biotechnology manufacturing center at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage, UK. In the first half of 2019, the center will start producing a fiber-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors.

Related Company

The facility producing fiber-based chromatography platform for more efficient biopharmaceutical purification is to be operational in 2019.
The facility producing fiber-based chromatography platform for more efficient biopharmaceutical purification is to be operational in 2019.
(Source: GE Healthcare)

Chalfont St Giles/UK — The fiber-based purification platform comprises material with a unique proprietary structure. This has the potential to significantly improve process speed, flexibility and robustness during purification, a key step in the manufacturing of biopharmaceuticals. Additional products will also be produced at the center to serve both laboratory and clinical applications.

Opening this new facility, which incorporates 280 m2 of cleanroom space, will mean there are now 20 people at the Stevenage facility, the company announced. The fiber-based purification products will be prepared in Stevenage before being further processed and finished in the company’s existing manufacturing facility in Cardiff, Wales.


According to Olivier Loeillot, General Manager, Bio Process at GE Healthcare Life Sciences, this technology will bring real efficiency and productivity advantages for biopharmaceutical manufacturers as they move towards integrated, connected or continuous operations. The fiber-based chromatography technology developed and manufactured in Stevenage will extend the company's start-to-finish bioprocess purification portfolio.

Biopharmaceuticals, such as monoclonal antibodies are the world’s fastest-growing class of medicine. The global market for biopharmaceuticals is estimated at more than $ 200 billion, and the market is growing around eight percent annually, GE states. All the top 10 biologic drugs by global revenue used their technologies in their manufacture.

The purification technology to be produced at the new facility came to GE Healthcare as part of the acquisition of Puridify, in November 2017. Puridify was founded in 2013 as a spin-out from University College London (UCL) and was based at the bio-incubator facility at the SBC, where GE Healthcare maintains an open laboratory aimed at providing SBC tenants with affordable access to advanced protein and cell analysis technologies.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent